SCHEMBL4255393

SCHEMBL4255393

Cc1cccc(/C=C/S(=O)(=O)NC(=O)c2ccc(F)cc2Cl)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PYGL P06737 3/20 0.43
FLT1 P17948 2/20 0.41
FLT4 P35916 2/20 0.41
KDR P35968 2/20 0.41
MAPT P10636 2/20 0.40
AGTR1 P30556 1/20 0.40
RXFP1 Q9HBX9 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NFE2L2 Q16236 1/20 0.40
HPGD P15428 1/20 0.39
MEN1 O00255 1/20 0.39
EGFR P00533 1/20 0.38
SORT1 Q99523 1/20 0.38
CYP2D6 P10635 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4255400 1.00 PYGL (0.43) PYGLFLT1FLT4KDRMAPT
SCHEMBL4257605 0.89 FLT1 (0.51) FLT1FLT4KDRAGTR1
SCHEMBL4260741 0.87 F2R (0.42) AGTR1KMT2ANFE2L2HPGDMEN1
SCHEMBL4260736 0.87 F2R (0.42) AGTR1KMT2ANFE2L2HPGDMEN1
SCHEMBL4255228 0.85 SORT1 (0.42) FLT1FLT4KDRAGTR1KMT2A
SCHEMBL4255220 0.85 SORT1 (0.42) FLT1FLT4KDRAGTR1KMT2A
SCHEMBL4256236 0.84 GRM4 (0.49) FLT1FLT4KDRAGTR1RXFP1
SCHEMBL4256232 0.84 GRM4 (0.49) FLT1FLT4KDRAGTR1RXFP1
SCHEMBL4262696 0.83 FLT1 (0.50) FLT1FLT4KDRAGTR1KMT2A
SCHEMBL4262689 0.83 FLT1 (0.50) FLT1FLT4KDRAGTR1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 PYGL 880/4885FLT1 2692/4885FLT4 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.